Net Cash Provided by (Used in) Operating Activities of Inhibikase Therapeutics, Inc. from 31 Mar 2020 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Summary
Inhibikase Therapeutics, Inc. quarterly and annual Net Cash Provided by (Used in) Operating Activities in USD history and change rate from 31 Mar 2020 to 31 Mar 2025.
  • Inhibikase Therapeutics, Inc. Net Cash Provided by (Used in) Operating Activities for the quarter ending 31 Mar 2025 was $4,103,530, a 6.1% decline year-over-year.
  • Inhibikase Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2024 was $19,148,067, a 5.9% decline from 2023.
  • Inhibikase Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2023 was $18,085,043, a 4.2% decline from 2022.
  • Inhibikase Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2022 was $17,351,103, a 21% decline from 2021.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Operating Activities, Quarterly (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Operating Activities, Annual (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Annual Change (%)

Inhibikase Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Operating Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $4,103,530 -$236,512 -6.1% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q1 2024 $3,867,018 +$2,105,112 +35% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q1 2023 $5,972,130 -$2,037,933 -52% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q1 2022 $3,934,197 +$23 +0% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q1 2021 $3,934,220 -$3,678,788 -1440% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q1 2020 $255,432 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021 2021 Q1

Inhibikase Therapeutics, Inc. Annual Net Cash Provided by (Used in) Operating Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $19,148,067 -$1,063,024 -5.9% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $18,085,043 -$733,940 -4.2% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $17,351,103 -$3,054,052 -21% 01 Jan 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY
2021 $14,297,051 -$13,167,696 -1166% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
2020 $1,129,355 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.